Minireviews
Copyright ©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Aug 14, 2014; 20(30): 10425-10431
Published online Aug 14, 2014. doi: 10.3748/wjg.v20.i30.10425
Personalizing medicine for metastatic colorectal cancer: Current developments
Andrea Marin Marques, Alice Turner, Ramon Andrade de Mello
Andrea Marin Marques, Centro Hospitalar do Médio Ave, Unidade de Santo Tirso, 4780-371 Santo Tirso, 4200-072 Porto, Portugal
Alice Turner, School of Medicine, University of Otago, 2 Riccarton Ave, Christchurch Central, 8011 Christchurch, New Zealand
Ramon Andrade de Mello, Department of Medical Oncology, Portuguese Oncology Institute (IPO PORTO), 4200-072 Porto, Portugal
Ramon Andrade de Mello, Department of Biomedical Sciences and Medicine, School of Medicine, University of Algarve, 8005-139 Faro, Portugal
Author contributions: All authors contributed to the manuscript.
Correspondence to: Ramon Andrade de Mello, MD, PhD, Department of Biomedical Sciences and Medicine, School of Medicine, University of Algarve. Edifício 7, ala nascente, 3o. andar, 8005-139 Faro, Portugal. ramondemello@gmail.com
Telephone: +351-289-800094 Fax: +351-289-800076
Received: February 12, 2014
Revised: March 19, 2014
Accepted: April 30, 2014
Published online: August 14, 2014
Processing time: 187 Days and 11.5 Hours
Core Tip

Core tip: Metastatic colorectal cancer (mCRC) treatment remains a challenge for clinicians worldwide. Recently, tumor molecular profile and tailored therapies are objects of great interest throughout the scientific community. Our manuscript will give the readers an interesting overview regarding the innovative drugs developing and recently approved for the treatment of mCRC.